This bill expands the federal "Right to Try" law to include investigational individualized medical treatments based on a patient's unique genetic profile, in addition to the experimental drugs already covered. The legislation allows patients diagnosed with life-threatening diseases or severely debilitating illnesses who have exhausted approved treatment options to request access to these personalized genetic treatments through eligible health care facilities, provided they receive informed consent from their physician. Manufacturers of these individualized treatments are permitted but not required to provide them to eligible patients. The bill requires physicians certifying patient eligibility to be in good standing with their licensing board and not compensated by the manufacturer, and it mandates that patients receive detailed written consent explaining their condition, approved treatments, the proposed experimental treatment, and potential outcomes. The legislation makes conforming changes to existing federal regulations to integrate individualized medical treatments into the current Right to Try framework without establishing new funding or implementation timelines.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.